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Neurobiology of Disease

Dynamic Analysis of Amyloid ␤-Protein in Behaving Mice
Reveals Opposing Changes in ISF versus Parenchymal A␤
during Age-Related Plaque Formation
Soyon Hong,1 Omar Quintero-Monzon,1 Beth L. Ostaszewski,1 Daniel R. Podlisny,1 William T. Cavanaugh,1 Ting Yang,1
David M. Holtzman,2 John R. Cirrito,2 and Dennis J. Selkoe1
1Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, and 2Department of
Neurology, Developmental Biology, Hope Center for Neurological Disorders, Alzheimer’s Disease Research Center, Washington University School of
Medicine, St. Louis, Missouri 63110

Growing evidence supports the hypothesis that soluble, diffusible forms of the amyloid ␤-peptide (A␤) are pathogenically important in
Alzheimer’s disease (AD) and thus have both diagnostic and therapeutic salience. To learn more about the dynamics of soluble A␤
economy in vivo, we used microdialysis to sample the brain interstitial fluid (ISF), which contains the most soluble A␤ species in brain at
steady state, in ⬎40 wake, behaving APP transgenic mice before and during the process of A␤ plaque formation (age 3–28 months).
Diffusible forms of A␤, especially A␤42 , declined significantly in ISF as mice underwent progressive parenchymal deposition of A␤.
Moreover, radiolabeled A␤ administered at physiological concentrations into ISF revealed a striking difference in the fate of soluble A␤
in plaque-rich (vs plaque-free) mice: it clears more rapidly from the ISF and becomes more associated with the TBS-extractable pool,
suggesting that cerebral amyloid deposits can rapidly sequester soluble A␤ from the ISF. Likewise, acute ␥-secretase inhibition in
plaque-free mice showed a marked decline of A␤38 , A␤40 , and A␤42 , whereas in plaque-rich mice, A␤42 declined significantly less. These
results suggest that most of the A␤42 that populates the ISF in plaque-rich mice is derived not from new A␤ biosynthesis but rather from
the large reservoir of less soluble A␤42 in brain parenchyma. Together, these and other findings herein illuminate the in vivo dynamics of
soluble A␤ during the development of AD-type neuropathology and after ␥-secretase inhibition and help explain the apparent paradox
that CSF A␤42 levels fall as humans develop AD.

Introduction
After decades of investigative focus on amyloid plaques in Alzheimer’s disease (AD), recent findings have led to a conceptual shift.
Emerging evidence suggests that the insoluble amyloid fibrils that
comprise plaques may not directly confer neurotoxicity but sequester small, diffusible assemblies of amyloid ␤-peptide (A␤)
that have been shown to potently alter synaptic structure and
function (Walsh and Selkoe, 2007). The recognition of A␤ oligomers as highly bioactive assemblies has furthered interest in
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detecting and analyzing soluble forms of the peptide for mechanistic, diagnostic, and therapeutic purposes. Although factors
other than A␤ dyshomeostasis contribute importantly to the
pathogenesis of AD (Pimplikar et al., 2010), virtually all potentially disease-modifying treatments currently under development are focused on decreasing or neutralizing this neurotoxic
peptide. Moreover, a reduced CSF level of A␤42 in subjects with
incipient or very early AD is one of the most promising biomarkers. Despite this therapeutic and diagnostic focus, we still lack
insight into the in vivo economy of the most soluble forms of A␤
in the brain during the development of AD-type pathology.
Here, we used brain microdialysis in awake and behaving
hAPP transgenic (tg) mice to gain an understanding of A␤ dynamics before and during the process of A␤ plaque formation.
Brain interstitial fluid (ISF) contains the A␤ pool that best reflects
the physiological secretion and fate of soluble species. Microdialysis in mouse models of AD and even human subjects is providing important insights into the dynamics of normal ISF A␤
economy (Brody et al., 2008; Cirrito et al., 2008; Kang et al., 2009)
and may help identify the earliest, most subtle A␤ changes that
occur as AD-type neuropathology begins. Given the power of this
in vivo sampling method, we performed hippocampal microdialysis on ⬎40 freely moving APP transgenic mice of increasing
age as a model of cerebral A␤ accumulation, and we searched for
changes in the quality and quantity of A␤ species as the brain
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accrues insoluble deposits and undergoes neuronal and glial injury. We systematically analyzed the nature of endogenous A␤
over time using sensitive sandwich ELISAs, immunoprecipitation (IP)/Western blotting (WB), native and denaturing PAGE,
and size exclusion chromatography (SEC). We then complemented these analyses by assessing the fate of radiolabeled A␤
microinjected at physiological concentrations as a surrogate of
newly secreted A␤, and the results help explain the fall of A␤42 in
the CSF of humans with AD. Together, these experiments describe the in vivo dynamics of the most soluble pool of brain A␤
during the process of AD-type amyloid plaque formation.

Materials and Methods
Mice. J20 line carrying hAPP minigene with FAD mutations KM670/
671NL and V717F (a kind gift from L. Mucke, Gladstone Institute, University of California San Francisco, San Francisco, CA) was maintained
on a C57BL6 ⫻ DBA2 background (Mucke et al., 2000). All animal
procedures were approved by the Harvard Medical School Institutional
Animal Care and Use Committee. Mice of both sexes were used in all
experiments.
In vivo A␤ microdialysis. Microdialysis was performed as previously
described (Cirrito et al., 2003): intracerebral guides were inserted following the coordinates for left hippocampal placement (bregma: ⫺3.1 mm,
2.5 mm lateral to midline, and 1.2 mm below dura at 12° angle). Perfusion buffer [1.5% bovine serum albumin in artificial CSF (in mM: 1.3
CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 NaCl, pH
7.35)] was perfused using probes with 35 kDa molecular weight cutoff
(MWCO) membranes (BR-2; Bioanalytical Systems) at flow rates 0.2–1
l/min with an infusion syringe pump (Stoelting). Microdialysates (ISF)
were collected using a refrigerated fraction collector (Univentor). Mice
were kept on 12 h light/dark cycles, and housed in a Raturn cage system
(Bioanalytical Systems), which allowed mice to resume normal activities.
Interpolated zero-flow method. The in vivo percentage recovery was
calculated as previously described (Cirrito et al., 2003). ISF was collected
from 3- and 24-month-old tg mice while varying the perfusion rates
(PR): 1.0, 0.8, 0.6, 0.4, and 0.2 l/min. A␤ levels were measured using the
6E10 A␤ Triplex ELISA (MesoScale Discovery) and the values obtained
at each PR were plotted versus the respective PR. The 100% recovery (i.e.,
the theoretical maximal amount of exchangeable ISF A␤ species occurring at a zero PR) was calculated by extrapolating back the curve to a
zero-flow rate. Then, for each PR, percentage recovery was determined
by calculating how much %A␤ was captured compared with the theoretical [A␤] at zero PR.
A␤ ELISA. For 6E10 A␤ Triplex ELISA, we used the MSD 96-well
MULTI-SPOT Human (6E10) A␤ Triplex Assay (MesoScale Discovery)
following the manufacturer’s protocol. Briefly, ISF samples were loaded
in duplicates onto MULTI-SPOT microplates precoated with antibodies
specific to the C termini of A␤38, A␤40, and A␤42 and detected with
SULFO-TAG-labeled 6E10 antibody. Light emitted upon electrochemical stimulation was read using the SECTOR Imager 2400A. For A␤(1–x)
ELISA, we followed a previously described protocol (Townsend et al.,
2011). Nunc MaxiSorp 96-well plates were used with 4G8 (to A␤17–24;
Covance) as capture and biotinylated 82E1 (to A␤1–16, IBL) as detection
antibodies. Signals were amplified with AttoPhos (Promega) and measured by Victor2 fluorescent plate reader (PerkinElmer).
Lactate, pyruvate, and glycerol measurements. Levels were measured
from ISF sampled at 0.2 l/min using the CMA600 analyzer at the Yale
Center for Clinical Investigation (sensitivities were as follows: lactate 0.02
mM, pyruvate 2 M, and glycerol 2 M).
Mouse brain sample preparation for biochemical analyses. Brains were
homogenized using a mechanical Dounce homogenizer with 20 strokes
at 4000 rpm in ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) and
protease inhibitors at 4:1 TBS volume:brain wet weight. Homogenate
was centrifuged for 30 min at 175,000 ⫻ g in a 4°C TLA100.2 rotor on
Beckman TL 100 (resulting supernatant is termed TBS extract). Pellet
was resuspended in 2% SDS using an 18 gauge needle, heated at 100°C for
10 min and spun at 21,130 ⫻ g in an Eppendorf 5435 for 10 min (resulting supernatant is termed SDS extract). Pellet was washed twice more in
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SDS, then incubated with 88% formic acid (FA) at room temperature for
2 h. Resulting supernatant (FA extract) was diluted 10⫻ with water and
lyophilized.
Immunoprecipitation and Western blot for A␤. ISF and brain extracts
(except FA extract, which was lyophilized and directly reconstituted in
LDS sample buffer before loading) were immunoprecipitated with AW8
polyclonal antibody to A␤ (1:100; gift from D. Walsh, Brigham and
Women’s Hospital) using Protein A (Sigma). For conventional SDSPAGE, a previously described protocol (Shankar et al., 2008) was followed. Samples were electrophoresed using 12% Bis-Tris gel and MES
SDS running buffer (Invitrogen), transferred onto 0.2 m nitrocellulose,
boiled, then blotted using monoclonal antibodies 6E10 (to A␤3– 8; Covance) and 4G8, and visualized using the LiCor Odyssey Infrared Imaging
System. For bicine/urea-based SDS-PAGE, a previously described system
(Klafki et al., 1996) was modified. Briefly, 11% T/2.6% C 8M urea separation gel was overlayered by 11% T/2.6% C 4M urea spacer gel and 4%
T/3.3% C comb gel. Gels were run at 12 mA for 1 h, then 34 W for 3.8 h.
Proteins were transferred to PVDF membranes, boiled then blotted with
6E10 with congo red, and detected using HRP and ECL Plus WB Detection Reagent (GE Healthcare).
Immunohistochemistry of brain sections. J20 APP tg brains at ages 3, 12,
and 24 months were fixed with 10% formalin, paraffin-embedded, then
sectioned at 8 m thickness, as previously described (Lemere et al.,
2002). R1282 polyclonal antibody was used to stain A␤ and the immunoreactivity was visualized using the Vector Elite horseradish–peroxidase ABC kit (Vector Laboratories) with diaminobenzidine (Sigma) as
the chromogen.
APP Western blotting. Mouse brains of 3- and 24-month-old tg mice
and wt littermates were homogenized in 1% (v/v) Nonidet P-40 STEN
buffer (in mM: 150 NaCl, 50 Tris, 2 EDTA) using a Teflon Dounce homogenizer. Brain lysates were loaded onto 4 –12% Bis-Tris gel, electrophoresed with MES SDS running buffer, transferred onto 0.2 m
nitrocellulose, then blotted with polyclonal antibody C7 (to full-length
APP and its C-terminal fragments) and anti-␣-tubulin polyclonal antibody (Thermo Scientific).
Size-exclusion chromatography. TBS extracts (250 l) or synthetic A␤
(2 ng) were eluted at 0.5 ml/min from a Superdex 200 10/300GL column
(GE Healthcare) with 50 mM ammonium acetate, pH 8.5. Resulting 1 ml
fractions were lyophilized, reconstituted in LDS sample buffer, and
heated at 65°C for 10 min. Samples were subjected to WB using 3D6 (to
A␤1–5; a gift from Elan) and the LiCor Odyssey Infrared Imaging System
or ECL Plus WB Detection Reagent (GE Healthcare).
Compound E treatment. Compound E (3 mg/kg; Axxora) was injected
intraperitoneally to mice undergoing microdialysis. Half-lives were calculated according to Cirrito et al. (2003).
Radioactivity assay. For ISF experiments, 3 l of 1 nM [ 125I]-␤-amyloid(1– 40) (PerkinElmer) were injected through a combination infusion
cannula and microdialysis probe (IBR-2; Bioanalytical Systems) at 0.2
l/min. ISF was collected hourly at 0.6 l/min, paused during the injection, then restarted 1 min after injection. For TBS extractions, 5 l of
[ 125I]-␤-amyloid(1– 40) were injected in paired mice (young and old).
Brains were harvested for TBS extract preparation 1.5 h postinjection.
125
I levels were counted using a LS6500 multipurpose scintillation counter (8 min counts).
Clear native PAGE and subsequent denaturation for SDS-PAGE. TBS
extracts were prepared from homogenized brains of 24-month-old tg
mice and wt littermates, then subjected to non-denaturing clear native
PAGE, which separates proteins with isoelectric point ⬍7 based on their
intrinsic charge (Wittig and Schägger, 2005). Briefly, samples were electrophoresed using native PAGE 4 –16% Bis-Tris gel (Invitrogen) with Bis-TrisHCl, pH 7.0, as anode and Tricine Bis-Tris, pH 7.0, as cathode buffers.
Proteins were then transferred onto 0.2 m PVDF (Millipore), boiled and
blotted for A␤ using monoclonal antibodies 2G3 and 21F12 (to A␤33– 40 and
A␤33– 42, respectively; gifts from Elan). For subsequent denaturation, we
excised two regions of the native PAGE gel following electrophoresis: the
⬎300 kDa and the 80 –230 kDa [based on NativeMark Unstained Protein
Standard (Invitrogen)]. The diced gels were heated at 100°C in denaturing
LDS sample buffer and supernatants were electrophoresed using 12% BisTris gel and MES SDS running buffer (Invitrogen) for Western blotting
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herein), we used a microdialysis probe
with a 35 kDa MWCO membrane in mice
expressing FAD-mutant human APP [J20
line (Mucke et al., 2000)]. When we intraperitoneally injected Compound E, a
potent and brain-penetrant ␥-secretase
inhibitor (Grimwood et al., 2005; Yan et
al., 2009), total ISF A␤ captured in microdialysates fell rapidly (t1/2, ⬃2 h) to baseline (Fig. 1a), showing that most of the ISF
A␤ we sampled by microdialysis in young
mice represents newly synthesized APP
cleavage products. To capture the A␤ species that best reflect the physiological levels, we performed microdialysis at a slow
perfusion rate of 0.2 l/min for up to 72 h,
as this allows optimal exchange of free A␤
into the probe. ISF samples were immuFigure 1. ISF A␤ obtained by microdialysis from behaving 3-month-old J20 hAPP tg mice. a, Rapid decline of ISF A␤ (t1/2, ⬃2
noprecipitated with a polyclonal A␤ antih) upon acute ␥-secretase inhibition in vivo in 3-month-old tg (vs wt littermate) mice. ISF sampled hourly at 1 l/min; Compound
serum
(AW8), and the precipitates were
E injected at time ⫽ 0 h. b, c, ISF collected at 0.2 l/min were immunoprecipitated with AW8 A␤ antiserum and subjected to two
separated
by denaturing PAGE and blottypes of SDS-PAGE. b, Conventional SDS-PAGE separates ISF A␤ into a ⬃4 kDa [monomers (M)] and a ⬃5 kDa A␤immunoreactive (lane 3) species. No dimers (D) were detected in ISF, but can be seen in the TBS-extract of a 24-month-old tg ted with pooled monoclonal antibodies to
mouse (lane 2) or synthetic (synth.) A␤ (lane 1). WB was performed with 6E10 plus 4G8. c, Bicine/urea SDS-PAGE resolved ISF A␤ the N terminus (6E10) and midregion
into three bands comigrating with synthetic A␤1–38, A␤1– 40, and A␤1– 42, plus a fourth faint band corresponding to A␤1–39. WB (4G8) of A␤. The ISF A␤ was separated by
was performed with 6E10. d, Using 6E10 A␤ triplex ELISA, we quantified A␤x–38, A␤x– 40, and A␤x– 42 in ISF (mean ⫾ SEM: 635 ⫾ conventional SDS-PAGE into two species:
70, 1937 ⫾ 311, and 592 ⫾ 58 pg/ml, respectively; n ⫽ 7 mice). e, Interpolated zero-flow method (mean ⫾ SEM; n ⫽ 3– 4 a 4 kDa monomer and a novel ⬃5 kDa
mice).
species, which ran approximately half the
time as a band (Fig. 1b) and the other half
as a smear (Fig. 4a). We did not detect
dimers (which run at ⬃6.5 kDa in these
gels; Fig. 1b) by IP/WB in the ISF of any of
the ⬎40 mice we examined in this study,
regardless of age. In vitro (test tube) microdialysis of synthetic A␤40 showed that
our 35 kDa MWCO membrane allowed
passage of dimers; however, their diffusion efficiency was low compared with
that of monomers (data not shown), suggesting that the lack of dimers in the ISF
samples could be due to the detection
limit of the technique. Next, we analyzed
the mouse ISF by bicine/urea SDS-PAGE,
Figure 2. Amyloid plaques develop and mature with age in J20 APP tg mice without significant changes in full-length (FL) APP which electrophoretically separates A␤
or in its proteolytic processing by ␤- or ␣-secretases. a, Hippocampal sections from fixed J20 APP tg brain were paraffin- peptides of different lengths (Klafki et al.,
embedded, then stained for A␤ using R1282 polyclonal antibody. Three-month-old tg sections were virtually plaque-free, 1996). ISF A␤ was resolved into three
whereas some plaques had formed by age 12 months. By 24 months, abundant diffuse and dense-core plaques populated the principal bands comigrating with synhippocampus. b, Representative blot of brain lysates of 3- and 24-month-old tg mice and wt littermate loaded onto denaturing
thetic A␤1–38, A␤1– 40, and A␤1– 42, plus a
SDS-PAGE, then blotted for full-length APP and its C-terminal fragments (CTFs) (WB was performed with polyclonal C7) or to
fourth faint band comigrating with A␤1–39
␣-tubulin (WB was performed with polyclonal tubulin-␣). c, Summary ratios of immunoreactive signals at 24- versus 3-monthold tg mice, for full-length APP and C-terminal fragments normalized to the ␣-tubulin signal. n ⫽ 3 mice per group; signal (Fig. 1c). Using a multiplex ELISA, we
confirmed the bicine/urea gel result that
quantification by Licor Odyssey.
A␤40 is the most abundant A␤ in ISF (Fig.
1d). The A␤42 /A␤40 ratio in the ISF of
using monoclonal antibody 3D6 (to A␤1–5; gift from Elan). Proteins were
young, plaque-free J20 mice was calculated to be ⬃0.3. Using the
visualized using the Licor Odyssey Infrared Imaging System.
interpolated zero-flow method (Jacobson et al., 1985; Cirrito et
Statistical analysis. Data were analyzed using PRISM (Graphpad Softal., 2003), we estimated the total soluble A␤ concentrations in
ware) for one- or two-way ANOVA, followed by Bonferroni post hoc test
hippocampal ISF of 3-month-old tg mice to be ⬃1.2 nM (Fig. 1e).
if means were significantly different by ANOVA, or Student’s t test, as
appropriate.

Results

Biochemical analysis of A␤ peptides that remain soluble in
the brains of young, behaving hAPP transgenic mice
To examine the quality and quantity of A␤ that remains soluble
and of low molecular weight in ISF in vivo (termed ISF A␤

ISF A␤ decreases with age as A␤ in brain parenchyma accrues
To elucidate how amyloid plaque development and maturation
affect the steady-state levels of brain ISF A␤, we sampled ISF from
the hippocampi of living J20 tg mice at three ages: preplaque (⬃3
months), early plaque deposition (⬃12 months), and abundant
and mature plaque deposition (⬃24 months) (Fig. 2a). The levels
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Figure 3. Levels of soluble ISF A␤ ⬍35 kDa in the brain fall with age. a– d, ISF was sampled from the hippocampi of 3- (preplaque), 12- (early plaque deposition), and 24-month old (abundant,
mature plaques) J20 tg mice. Using A␤ triplex ELISAs, we found that A␤x–38 (a), A␤x– 40 (b), and A␤x– 42 (c) all decreased with age (means ⫾ SEM; n ⫽ 7, 4, 7 mice at 3, 12, and 24 months,
respectively). One-way ANOVA, followed by Bonferroni test: *p ⬍ 0.05, **p ⬍ 0.01, and ***p ⬍ 0.001 versus 3 months values; #p ⬍ 0.05 versus 12 months values. d, Proportional levels of A␤38,
A␤40, and A␤42, where each peptide was normalized to its level at 3 months. A␤42 declined the most (80% by 24 months vs 3 months). ***p ⬍ 0.0001 by two-way ANOVA with age as a variant.
e, At 0.2 l/min, the perfusion rate used to collect all ISF samples in Figures 3 and 4, we obtained comparable percentage recoveries of microdialyzable A␤ in the two extreme ages (⬃63 ⫾ 3% in
3-month-old tg mice and ⬃66 ⫾ 2% in 24-month-old tg mice, means ⫾ SEM; n ⫽ 3– 4 mice). f, g, Ratios of lactate to pyruvate (f ) and glycerol (g) levels in the ISF microdialysates were not altered
with age (means ⫾ SEM; n ⫽ 3– 8 mice).
Table 1. Theoretical concentrations of microdialyzable ISF A␤ in vivo at zero-flow rate
A␤38 (pg/ml)
A␤40 (pg/ml)
关ISF A␤兴 of J20 tg mice

A␤42 (pg/ml)

A␤42:A␤40

3 mo

24 mo

3 mo

24 mo

3 mo

24 mo

3 mo

24 mo

930

658

2975

1231

880

166

0.30

0.13

Concentrations of endogenous hippocampal ISF A␤38 , A␤40 , and A␤42 were calculated by extrapolating the curves generated from the interpolated zero-flow method to zero PR (Fig. 5). Ratios of A␤42 /A␤40 in the ISF of 3- and
24-month-old tg mice were calculated to be ⬃0.30 and 0.13, respectively, reflecting a higher drop of A␤42 versus A␤40 in 24-month-old tg mice.

of holoAPP and its C-terminal fragments
generated by ␤- and ␣-secretases were
constant over the 3- to 24-month ISF
sampling period (Fig. 2b), suggesting that
A␤ production via APP proteolytic processing does not change appreciably over
age. As quantified by multiplex A␤ ELISA,
all three A␤ peptides measured in ISF
(A␤x–38, A␤x– 40, and A␤x– 42) decreased
over time to levels that were significantly
reduced by 24 months (Fig. 3a–c shows
absolute values; Fig. 3d shows proportional levels). As the individual peptides
fell to different degrees, the A␤42/A␤40 ratio in the ISF shifted from 0.3 at 3 months
to 0.13 at 24 months. We estimated that
the total soluble A␤ concentrations in
hippocampal ISF decreased from ⬃1.2 nM
in 3-month-old tg mice to ⬃0.5 nM in 24month-old tg mice (for concentrations of
individual A␤ peptides in hippocampal
ISF of 3- and 24-month-old tg mice, see
Table 1). The similar percentage recovery
of microdialyzable A␤ at 3 and 24 months
(measured at five flow rates) indicates that
the age-dependent decrease in ISF A␤ is
not due to technical issues with the microdialysis system (Fig. 3e). We measured
analytes other than A␤ present in the ISF
to see whether they are also altered with
age, in particular, lactate, pyruvate, and
glycerol. The ratio of lactate to pyruvate is

Figure 4. A␤ in all pools of brain parenchyma accrue with age while those that remain diffusible in the ISF declines. a, Representative
IP/WBs of A␤ species from brains of the same mice right after microdialysis, in four pools: ISF, TBS extracted (ext), SDS extracted, and FA
extracted.Allpools(exceptFAextracted,whichwaslyophilizedandstraight-loadedontothegel)wereimmunoprecipitatedwithAW8and
blottedwith6E10and4G8.Synthetic(synth.)A␤ runalongsideforquantification.Perfusionbuffer(PB)andTBSwereimmunoprecipitated
as negative controls. b– e, Quantification of IP/WBs from 21 mice shows ⬃50% decrease in absolute values of ISF A␤ between 3 and 12
months(notsignificantbyone-wayANOVAfollowedbyBonferronitest)(b),withasharpriseinTBS-(c),SDS-(d),andFA-(e)extractedA␤
(picogramspermilligramswetbraintissue).f,g,RatiosofISFtoTBS-solubleA␤ (f)ortototalparenchymalA␤ (g)calculatedforeachmouseand
shownasmeanratio⫾SEM;n⫽7micepergroup.A␤ quantifiedbyLicorOdysseyimagingandanalyzedbyone-wayANOVAandBonferronitest:
**p⬍0.01and***p⬍0.001versus3months; #p⬍0.05and ##p⬍0.01versus12months.D,Dimers;M,monomers.
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Figure 5. Microdialysis at slower perfusion rates reveals age-dependent changes in ISF A␤.
ISF were collected from hippocampi of 3- (plaque-free) and 24- (plaque-rich) month-old tg
mice while varying the PR. Samples were then quantified using 6E10 A␤ triplex ELISA. a– c, At
PR 1 l/min, no age-dependent changes in any of the three peptides were detectable; however, at slow PRs (especially 0.2 l/min), significant differences were noted, particularly in
A␤40 and A␤42. d, Sum of the three A␤ peptides measured (total A␤). Values are means ⫾
SEM, n ⫽ 3–7 mice; p values by two-way ANOVA and Bonferroni test.
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A␤ in ISF obtained in vivo with three pools of brain parenchymal
A␤ isolated from the same mice right after the dialysis: TBS extract (traditionally defined as the soluble A␤ fraction), detergent
(SDS) extract (aggregated and membrane-associated A␤), and
FA extract [A␤ from highly insoluble deposits, including plaque
cores (Masters et al., 1985; Selkoe et al., 1986)]. As reported previously for the J20 line and other APP tg mice (Johnson-Wood et
al., 1997; Hsia et al., 1999; Mucke et al., 2000; Kawarabayashi et
al., 2001; Shankar et al., 2009), we observed an age-dependent rise
in levels of all three pools of parenchymal A␤ (Fig. 4a). Both the
SDS and FA extracts rose sharply with age (Fig. 4a,d-e). A␤ in the
TBS extract did not rise substantially until 24 months, an age at
which we regularly observed SDS-stable dimers in this fraction
(Fig. 4a,c). In contrast to these age-dependent rises in parenchymal A␤, there was a decline in the ISF. We observed a 50% decrease in total absolute ISF A␤ levels between 3 and 12 months
(Fig. 4b), before there was an appreciable rise in the TBS extract
(Fig. 4c). We next analyzed the values in each mouse to determine
what portion of its TBS-soluble A␤ remains dialyzable in vivo,
and observed a fivefold decline in the ISF/TBS ratio between 3
and 12 months (Fig. 4f ). When normalized to total brain parenchymal A␤, the relative ISF level declined even more (Fig. 4g).
Thus, all A␤ pools in brain parenchyma
rise with age, while that which remains
diffusible in ISF in vivo sharply declines.

Altered dynamics of soluble A␤ in
plaque-rich versus plaque-free mice
Sampling the ISF at slower perfusion rates
(which allows for more efficient dialysis of
ISF solutes) revealed age-dependent changes
in ISF A␤ (Fig. 5). In particular, this method
revealed significantly decreased diffusion of
endogenous A␤40 and A␤42 into the microdialysis probe in 24-month-old compared
with 3-month-old mice. To better understand the basis for this marked decrease in
recovery of diffusible ISF A␤ in the presence
Figure 6. Dynamic shift in the in vivo economy of A␤ once plaques develop. a– c, Soluble synthetic [ 125I]A␤1– 40 at a physio- of abundant plaques, we approximated the
logical concentration (1 nM) was injected intrahippocampally via a small cannula on the microdialysis probe in awake, behaving fate of newly secreted A␤ molecules by
mice at ages 3–7 (plaque-free) or 24 –27 (plaque-rich) months, and radioactivity was recovered in the ISF by microdialysis (a) and exogenously administering radiolabeled
from the TBS extracts of the brains (b). Means normalized to amounts in the plaque-free mice (100%) ⫾ SEM; n ⫽ 3– 4 mice per soluble A␤. We acutely injected soluble syngroup; p values are one-tailed t tests versus 3–7 months. c, Amount of [ 125I]A␤ recovered in the first hour of injection plotted thetic [ 125I]A␤
1– 40 at a physiological conversus the endogenous A␤ levels sampled from same mice before injection. d–f, ISF A␤42 is minimally affected by Compound E in centration (1 nM), via a small cannula
plaque-rich mice. d, Representative graph of hourly ISF A␤ levels after Compound E injection (0 h) into 24-month-old plaque-rich
attached to the microdialysis probe, into the
mice while collecting their brain ISF at 0.6 l/min. Levels were normalized to levels of each A␤ species before injection. e,
hippocampal ISF of either age 3–7 months
Quantification of the individual ISF A␤ peptides in 24-month-old plaque-rich mice for the first 5 h postinjection (means ⫾ SEM,
n ⫽ 3 mice; p value is by one-way ANOVA). f, Hourly ISF A␤ levels after Compound E injection (0 h) in a 3-month-old plaque-free (plaque-free) or age 24 –27 months (plaquerich). We then measured the ability to retg mouse.
cover the radiolabeled peptide from the ISF
by microdialysis. From the ISF of the
an established marker of the redox state of cells; glycerol is an
plaque-rich mice, we recovered only 45% of the injected peptide that
integral component of cellular membranes, and changes in its
was recovered from the ISF of plaque-free mice (p ⬍ 0.0001) (Fig.
level can reflect degradation of membranes (Ungerstedt and Ros6a). The amounts of the injected [ 125I]A␤ that were recovered at the
two ages correlated well with the respective endogenous A␤ concentami, 2004). Neither the lactate-to-pyruvate ratio nor the level of
trations in the ISF before injection: the [ 125I]A␤ levels observed in
glycerol in ISF changed significantly during our 3–24 months
the first hour and the endogenous A␤ levels just before injection
sampling period (Fig. 3f,g), suggesting that the decrease in A␤ is
not associated with altered intermediary metabolism or perturwere both high in young mice and low in old mice (Fig. 6b), indicatbation of cell membrane integrity.
ing that the acutely injected radiopeptide achieves a similar equilibNext, we sought to identify the pathophysiological relationrium as the endogenous A␤ has at steady state. We hypothesized that
in plaque-rich mice, the acutely administered monomer is more
ship between ISF A␤ and the accrual of increasingly less soluble
A␤ in brain parenchyma during the development of AD-type
readily incorporated into their abundant A␤ deposits and thus is less
neuropathology. Using a sensitive IP/WB method (Walsh et al.,
recoverable in the ISF. To address this idea, we quantified the radio2002; Shankar et al., 2008), we compared the quantity and type of
activity retained in the TBS extracts of brain. We saw a substantially
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higher amount of the fresh, exogenous radiopeptide retained in the TBS extracts of
the older mice (Fig. 6c). In the short time
frame we conducted these analyses (i.e., the
first 90 min after administration), we did
not detect significant levels of radioactivity
in the SDS and FA fractions. Together, these
results suggest that in plaque-burdened
mice, newly generated soluble A␤ released
into the ISF readily accrues onto parenchymal deposits, accounting for its lower
steady-state level in the ISF.
The level of ISF A␤42 in plaque-rich
mice is minimally affected by acute
␥-secretase inhibition
To assess whether the ISF A␤ we measured in plaque-rich older mice also represents recent APP cleavage products, as
we had determined in young mice (Fig.
1a), we acutely inhibited ␥-secretase in
vivo with Compound E. There was a rapid
decline of A␤38 and A␤40 (⬃60% fall in
the first 3 h; t1/2, ⬃1.9 h and ⬃2.3 h, respectively), whereas A␤42 declined significantly less (⬃20% fall) (Fig. 6d,e). In
contrast, all three peptides fell together in
young plaque-free mice during the first
5 h after shutting down new production
with Compound E (Fig. 6f ). As A␤42 is the
species reported to accumulate much
more into plaques than the other, more
abundantly generated A␤ peptides in both
AD patients and APP mice (Iwatsubo et
al., 1994; Johnson-Wood et al., 1997),
these results suggest that most of the soluble A␤42 peptide that populates the ISF
pool in plaque-rich mice is not derived
primarily from new A␤ biosynthesis but
rather from the large reservoir of less soluble A␤42 in the brain parenchyma. The
results also indicate that acute ␥-secretase
inhibition is less effective in lowering A␤42
in plaque-rich brains.

Figure 7. Saline brain extracts of tg mouse exists principally in assemblies ⬎500 kDa in native form. a, Bicine/urea SDS-PAGE
shows the principal A␤ peptides present and their relative expression levels in ISF and TBS extracts of 3-, 12-, and 24-month-old tg
mice. IP was performed with AW8; WB was performed with 6E10. b, Quantification (by ImageJ software) of A␤42/A␤40 ratios in
plaque-free 3-month-old tg mice (p value by one-tailed t test; n ⫽ 3 each). c, Non-denaturing SEC of TBS extracts (ext) of 3- and
24-month-old tg mice performed on a Superdex 200 SEC column followed by SDS-PAGE of each SEC fraction. Synthetic (synth.)
A␤40 run on the same SEC column for comparison. WB was performed with 3D6. d, TBS extracts from a 24-month-old tg mouse and
its wt littermate subjected to clear native PAGE and blotted for A␤. WB was performed with 2G3 plus 21F12. e, Excision of the
⬎300 kDa region and subsequent electrophoresis by denaturing SDS-PAGE showed that this high MW material is disassembled
into low MW SDS-stable A␤ species. WB was performed with 3D6. T, Trimers; D, dimers; M, monomers; MWM, MW marker.

Saline-extractable A␤ of brain
parenchyma in its native form appears
to exist principally in assemblies >500
kDa
Bicine/urea SDS-PAGE gels showed that
the A␤ peptide distribution differed between the ISF and TBS-extracted pools at
all ages (Fig. 7a). Even at age 3 months, when the brain has virtually no plaques, A␤40 was the primary A␤ species in ISF, while,
in the TBS-extracted pool, A␤42 was already the more abundant
peptide at steady state, despite the fact that it is generated in much
lower amounts than A␤40 (Fig. 7a). Accordingly, the A␤42/A␤40
ratio differed markedly between the ISF (low ratio) and TBS extract (very high ratio) (Fig. 7b). This stark difference led us to
question the general assumption that the brain A␤ pool that
comes into solution upon mechanical homogenization in physiological buffers represents the truly soluble pool (McLean et al.,
1999; Walsh and Selkoe, 2004; Shankar et al., 2009). We per-

formed non-denaturing SEC on the TBS extract and subjected
the resultant SEC fractions to SDS-PAGE for WB analysis. Surprisingly, most A␤ in the TBS extracts of plaque-free (3 months
tg) mice eluted in the void volume of a Superdex 200 SEC column
[suggesting a molecular weight (MW) ⬎500 kDa], and this material ran principally as monomers when electrophoresed on a
denaturing gel (Fig. 7c, fractions 6 and 7). The SEC elution profiles of TBS extracts from 3- and 24-month-old tg mice were
similar and differed sharply from that of synthetic A␤40 peptide
alone (Fig. 7c). In accordance with this, A␤ in TBS extracts from
24-month-old tg mice ran as an aggregated, high MW complex
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A␤ in the hippocampus before and during
the process of A␤ plaque formation. Our
results show that A␤ peptides, which remain soluble and of low molecular weight
in the interstitial fluid in vivo, decrease
significantly— both absolutely (Figs. 3–5,
7a) and especially in relation to the soluble A␤ extractable from brain membranes
(Fig. 4d)—as plaques accumulate. A␤42
decreases the most among the three major
A␤ peptides in the ISF; in agreement with
Figure 8. Summary of the temporal changes in the four A␤ brain pools. a, Decreases with age in all three in vivo ISF A␤ peptides this, A␤42 rises the most in the less soluble
measured by 6E10 A␤ triplex sandwich ELISA (for details, see Fig. 3). b, The fold-decrease measured by ELISA (significant between A␤ pools in the brain parenchyma (Figs.
ages 3 and 24 months by two-way ANOVA; see Fig. 2) is comparable to the fold-decrease measured by IP/WB (though the latter was 3, 7a), keeping with its documented prinot significant by one-way ANOVA; for details, see Fig. 4). The total amount measured by IP/WB analysis method was only ⬃30% mary role in oligomerization and plaque
of the total amount measured by ELISA. c, IP/WB analysis of A␤ in brain tissue. By ⬃24 months, there was a steep increase in
formation. Figure 8 provides summaries
insoluble (SDS- and FA-extracted) A␤. The TBS-extracted A␤ from the same mice did not rise until 24 months and then only very
of the temporal changes documented in
slightly. Values are means ⫾ SEM from Figures 3 and 4.
this study.
Of special clinical relevance is that our
discovery of an age-dependent decrease in
ISF A␤42 may be analogous to the widely
documented selective decrease in soluble
A␤42 in human (AD) CSF (Motter et al.,
1995). In humans, CSF levels of A␤42 appear to relate inversely to amyloid plaque
burden, degree of brain atrophy, and severity of cognitive deficits in humans
(Motter et al., 1995; Fagan et al., 2009;
Shaw et al., 2009). Our dynamic studies of
the change in endogenous ISF A␤ and of
the fate of radiolabeled A␤ before versus
after plaque initiation offer strong evidence from controlled animal experiments for the hypothesis that soluble A␤42
in humans falls in the CSF because it is
sequestered into increasingly insoluble
Figure 9. A hypothetical model of A␤ in vivo dynamics before versus after plaque formation based on data herein. Several parenchymal deposits as AD develops.
factors contribute to steady-state A␤ levels in brain ISF. There is a constant supply of A␤ in the ISF pool generated by new APP
What are the driving forces leading to
processing (A␤40 ⬎⬎ A␤38 ⫽ A␤42 ⬎ A␤39), and this generation appears to change little with age. ISF A␤ can be proteolytically the sharp decline of diffusible A␤ species
degraded, cleared locally by glia and/or transported across the blood brain barrier (BBB). Soluble A␤ starts aggregating at an early
as AD-like pathology progresses with age?
age in brain parenchyma, as evidenced by the ⬎500 kDa TBS-extractable pool as well as an SDS-extractable pool in 3-month-old
The constant levels of both full-length
plaque-free mice. The most abundant pools in a plaque-free brain are the ISF pool and the SDS-extractable pool. In a plaque-rich
brain, however, equilibrium between pools is greatly altered by the overwhelming amount of aggregated A␤, which act as a sink, APP and the C-terminal fragments generthereby diminishing the steady-state ISF pool. Plaques may also act as a contributor to the ISF pool, where A␤42, the most ated by ␣- and ␤-secretases suggest that
abundant peptide in plaques (and also the most decreased in the ISF) diffuses back into the ISF. HMW, High MW (i.e., ⬎500 kDa). the fall we observe is not due to a decrease
of cellular production of A␤. We also saw
no evidence for a perturbation of cell
membrane integrity, a change in an indion a clear native PAGE gel, whereas synthetic A␤40 ran close to
cator of intermediary metabolism, or altered spontaneous behavthe dye front (Fig. 7d). Excision of the ⬎300 kDa region and
ior (eating, exploring, grooming, etc.) in the mice, arguing
subsequent denaturation in LDS sample buffer yielded lower
against general cytotoxicity or cell death as an explanation for the
MW A␤ species, including monomers (Fig. 7e).
drop. Thus, we obtained no evidence that decreased neuronal
Discussion
activity or decreased A␤ production explains the drop in soluble
ISF A␤ as mice accrue amyloid deposits. Rather, the decrease in
Although factors other than A␤ dyshomeostasis contribute importantly to the pathogenesis of AD (Pimplikar et al., 2010), most
ISF A␤ occurred simultaneously with rises of insoluble A␤ in the
SDS- and FA-extractable pools (Figs. 3, 4). Furthermore, the dispotentially disease-modifying treatments currently under develtinct dispositions of soluble radiolabeled A␤ injected at physioopment are focused on decreasing or neutralizing this neurotoxic
logical concentrations directly into the ISF in plaque-free versus
peptide. Moreover, a reduced CSF level of A␤42 in subjects with
incipient or very early AD is one of the most promising biomarkplaque-rich animals provide insight into a shift in A␤ economy:
in plaque-rich mice, A␤ becomes rapidly less diffusible and more
ers. Despite this therapeutic and diagnostic focus, we still lack
associated with the loosely membrane-bound (TBS-extractable)
insight into the in vivo economy of soluble A␤ in the brain as
AD-type pathology forms. Here, we used the powerful method of
pool (Fig. 6). This dynamic shift leads us to hypothesize that once
brain microdialysis in awake, behaving hAPP transgenic mice to
an A␤ peptide binds to membranes and/or plaques, it is sequestered there and becomes less diffusible, at least temporarily, leadgain understanding of the dynamics of the most soluble forms of
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ing to decreased recovery during microdialysis, consistent with a
report of lengthened A␤ clearance time in old versus young APP
transgenic mice (Cirrito et al., 2003).
Indirect evidence for a converse pathway suggests that such
membrane association is not irreversible. Our finding that upon
acute ␥-secretase inhibition there was significantly less fall in ISF,
specifically of A␤42 (which is much more abundant in plaques),
suggests that plaques contribute to a dynamic equilibrium between soluble and insoluble A␤42 pools in the brain and thus help
regulate the steady state of ISF A␤ in aged mice (for a model, see
Fig. 9). This concept is consistent with evidence that amyloid
plaques in APP transgenic mice appear to act as a local reservoir
of loosely associated A␤ that can diffuse from plaques and populate a halo of oligomeric and monomeric A␤ immediately surrounding the amyloid core (Spires et al., 2005; Koffie et al., 2009).
It will be interesting to see whether acute alteration of one particular A␤ pool (e.g., via agents such as antibodies that can selectively bind aggregated A␤ or agents that only sequester the fully
soluble ISF pool) will have transient or lasting effects on the equilibrium maintained among the A␤ pools.
A␤ in aqueous extracts of homogenized cerebral cortex has
been termed by our group and others as the “soluble A␤” pool
and is thought to be derived from ISF and cytosol, not necessarily
from particulates such as amyloid deposits (Gravina et al., 1995;
Lue et al., 1999; McLean et al., 1999; Walsh and Selkoe, 2004;
Shankar et al., 2009); the rise in this pool was thought to reflect a
rise in diffusible A␤ in vivo. However, we show here that A␤
peptides in aqueous parenchymal extracts differ significantly in
quality and quantity from those that remain of low MW in the ISF
pool. Furthermore, using non-denaturing SEC and native gels,
we show that much native A␤ in the TBS extracts of APP transgenic mouse brains, even at a preplaque age of 3 months, exists in
assemblies ⬎500 kDa, extending similar data on the aqueous
extracts of AD brains (Shankar et al., 2008). Thus, aqueous extracts of A␤ may principally reflect aggregated A␤ peptides
bound to cell membranes (in young mice) and to membranes and
plaques (in older mice) but which remain water-extractable.
Given this new understanding that aqueous extracts of brain
may not reflect the truly diffusible A␤ species in vivo, it will be
important to examine the nature of synaptotoxicity in the different A␤ pools, including the ISF pool and the TBS-extracted pool,
which is currently thought to principally contain the toxic oligomeric species. Interestingly, we have not detected SDS-stable
dimers in any of our ISF microdialysates to date, which could be
due in part to the limits of detection. Using a test tube model of
our microdialysis technique, we found that synthetic A␤ dimers
(⬃8 kDa) crossed over the 35 kDa MWCO membrane; however,
the diffusion efficiency of dimers was poor compared with that of
monomers (data not shown). Therefore, we cannot exclude the
existence of low levels of soluble dimers in the ISF of hAPP transgenic mice. Our results may instead suggest that soluble dimers
and other oligomers do not actually exist per se in the most diffusible brain pool (ISF); rather, newly formed oligomers (with
their exposed hydrophobic amino acids) may distribute quickly
onto hydrophobic surfaces (cell membranes and/or amyloid
deposits).
As regards the implications of our findings for the pathophysiology of AD, it will be important in future studies to attempt to
detect any bioactivity of the ISF A␤ pool at the different plaque
stages of APP transgenic mice. Whereas the ISF of young, plaquefree mice acts as a reservoir mainly for the acute cellular production of A␤, ISF in plaque-rich mice seems to be a reservoir for
both new A␤ production and A␤ that diffuses from membrane-

and plaque-bound deposits (as evidenced by the finding that ISF
A␤42 levels do not fall significantly upon acute inhibition of
␥-secretase). Whether the A␤42 that comes off of parenchymal
deposits into the ISF is pathogenically important (compared with
A␤ in the ISF of plaque-free brains) will be important to
determine.
In conclusion, these dynamic analyses provide unique insights
into the generation of first fully soluble and then increasingly less
soluble A␤ species during age-related accrual of AD-type amyloid
deposits in living animals. Based on the usefulness of these preclinical data, we suggest a provocative approach toward potentially extending such studies to humans. Patients with normal
pressure hydrocephalus (NPH), which is typified by a clinical
triad of subacutely developing dementia, incontinence, and gait
ataxia (Relkin et al., 2005; Shprecher et al., 2008), are frequently
offered a neurosurgical procedure by which a ventriculoperitoneal shunt is inserted to chronically drain the excess ventricular
CSF to the peritoneal cavity and thus potentially improve the
patients’ NPH symptoms. Several studies of simultaneously obtained cortical biopsies have shown that some or many such
shunted patients show amyloid plaques and neurofibrillary tangles indistinguishable from those in typical AD patients (Del Bigio et al., 1997; Bech et al., 1999; Golomb et al., 2000; Hamilton et
al., 2010). This co-occurrence suggests that obtaining institutional review board approval to perform a brief (12–24 h) placement of a microdialysis probe at the time of an NPH shunt
placement could enable in vivo analysis of ISF A␤ peptides in
humans with varying degrees of A␤ deposition. We propose that
such controlled clinical research studies in appropriate patients
be considered to obtain direct information about the economy of
the most soluble species of brain A␤ (those in ISF) as a function of
the level of cerebral ␤-amyloidosis in humans.
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